Background: Informal payments can cause delayed access to health care services, forcing people to sell their properties for cost of treatment; and as a result, they lose trust in the health system. Considering the importance of this issue, this study was conducted in 2016 to identify solutions to reduce and eliminate informal payments in Iran’s health system.    Methods: Initia...

INTRODUCTION Imagine that CureCo, Inc., is the exclusive seller of a patented product that yields hundreds of millions of dollars per year in revenues. CopyCo International announces its intention to market the product and compete with CureCo. CureCo promptly sues CopyCo for patent infringement. A federal court holds that the patent is invalid, appearing to clear the way for CopyCo to enter the...

Background One of the objectives of the health transformation plan (HTP) in Iran is to reduce out-of-pocket (OOP) payments for inpatient services and eradicate informal payments. The HTP has three phases: the first phase (launched in May 5, 2014) is focused on reducing OOP payments for inpatient services; the second phase (launched in May 22, 2014) is focused on primary healthcare (PHC) and the...

#### Notable in Neurology This Week This issue features an article that examines the effect of intensive arm motor rehabilitation for patients >90 days after a stroke; another investigates financial conflicts interest associated with payments from pharmaceutical and medical device companies US authors neurology journals. A featured Views & Reviews factors influence selection Tourette syndrome ...

Under the table or informal payments in several middle and low income countries is a serious impediment to health care reform. These payments are effectively a form of systemic corruption. This report shows the efforts of a patient who seek health care for his ankle while being requested to pay under the table in hospital and private clinic. The data were collected by interview and surveying pa...

A nyone who has experienced the assault of the pharmaceutical industry's marketing campaigns would appreciate Jennifer Berry's one-person play Big Pharma: The Rise of the Anti-Depressant Drug Industry and the Loss of a Generation. Since the mid-1990s, spending on drug promotion has grown steadily, reaching $21 billion in 2002. Berry explores the fallout of this expanded marketing blitz through ...

Rising costs in pharmaceutical expenditure have become a major concern for policy makers in Germany over the last years. Therefore the pharmaceutical market in Germany has been increasingly targeted by different kinds of regulations, focussing both on the supply and the demand side, using price, volume and spending controls. Specific regulations include price reductions, reference pricing, phar...

We are in a period of unprecedented scrutiny of the relationships between the pharmaceutical industry and doctors [1–4]. Legislators are now considering how they might become involved in the regulation of these practices. This is a telling comment on the perceived failure of the medical profession to regulate itself and of self-regulation by industry. But reliable and comprehensive data on the ...